Northwire Canada EditionThursday, October 15, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4% GOLD 4107.90 −1.7% SILVER 55.88 −6.1% COPPER 6.62 −1.6% OIL 95.09 +1.0% PALLADIUM 1096.50 −2.7% CIA 2.64 −0.4% BTO 7.09 −4.3% MCI 0.155 +0.0% CAN 0.065 +0.0% BLDS 0.335 +8.1% SAO 0.050 +0.0% SF 0.315 +0.0% BEA 0.055 −15.4% BMM 3.90 +11.1% AUGC 0.295 −13.2% MFG 3.34 −3.8% CDE 21.33 −7.7% CYG 0.160 −5.9% RSMX 0.100 −4.8% TUF 0.830 −5.7% GPG 0.285 −3.4%
Other

2026 New Year's Greetings from the CEO

By The Northwire Desk — AI Analysis Jan 06, 2026 · 09:00 4875 · None None
4875 · Price

Executive Summary

  • Completed patient enrollment for three MediciNova clinical trials in 2025, positioning the company to generate pivotal data in 2026.
  • Launched a large‑scale Expanded Access Program for ALS supported by a $22 million NIH grant, with 87 patients enrolled across 12 U.S. sites as of Dec 15, 2025.
  • Provided timelines for upcoming top‑line results: COMBAT‑ALS (Phase 2b/3) expected by year‑end 2025; MN‑001‑NATG‑202 (Phase 2) data anticipated summer 2026.

Key Details

  • MN‑166 (ibudilast) – COMBAT‑ALS Study (Phase 2b/3, ALS):
  • Patient enrollment completed September 2025.
  • Double‑blind treatment period runs 12 months; last participant to finish by late 2025.

  • Data analysis will commence thereafter with top‑line results targeted for year‑end 2025.

  • Expanded Access Program for ALS:

  • Initiated March 2025, funded by a $22 million NIH research grant.

  • As of Dec 15, 2025: 12 U.S. sites active; 87 patients enrolled.

  • MN‑166 – OXTOX Study (Phase 2b, chemotherapy‑induced peripheral neuropathy):

  • Enrollment completed December 2025.

  • Participants will remain on treatment until disease progression or discontinuation criteria are met.

  • MN‑001 (tipelukast) – MN‑001‑NATG‑202 Study (Phase 2, hypertriglyceridemia/NAFLD/T2DM):

  • Enrollment completed November 2025.
  • Top‑line data expected summer 2026.

  • Recent academic collaboration identified a novel mechanism whereby MN‑001 and its metabolite MN‑002 modulate cholesterol and lipid metabolism, reinforcing development rationale.

  • Future Outlook (2026):

  • Company expects to leverage completed enrollments to file regulatory submissions pending positive trial outcomes.
  • Continued focus on advancing both MN‑166 and MN‑001 pipelines toward pivotal approvals.

Notable Quotes

“The year 2025 was marked by global uncertainty… Despite these challenges, MediciNova achieved significant milestones…” – Yuichi Iwaki, President & CEO

All forward‑looking statements are subject to risks and uncertainties detailed in the release.

Read the original news release →

More from None

Jun 30, 2026 · 08:00

Clinical-stage biotech advances late-stage neurology and metabolic assets with H2 2026 data catalysts on track.

Other Jun 08, 2026 · 08:00

Late-stage biotech advancing MN-166 across neurology and oncology, with patent wins reinforcing IP moats while pivotal clinical data remains pending.

M&A / Property May 26, 2026 · 19:00

MediciNova Clears Trial Hurdle for MN-001; Q3 Data Release Looms Amidst ALS Pipeline Progress

Other Apr 27, 2026 · 19:00

MediciNova’s Ibudilast Gains Brain Metastasis Validation Ahead of ALS Readout

Other Jan 29, 2026 · 18:00

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN-166 (ibudilast) in ALS patients

Other Dec 18, 2025 · 06:00

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

Other